Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.
written on 19.03.2014
Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use
